ASP 9853

Drug Profile

ASP 9853

Alternative Names: ASP9853

Latest Information Update: 21 May 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Astellas Pharma
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 12 May 2014 Discontinued - Phase-I for Cancer in USA (PO)
  • 31 Aug 2012 Phase-I clinical trials in Cancer in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top